JP2018529363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529363A5 JP2018529363A5 JP2018517183A JP2018517183A JP2018529363A5 JP 2018529363 A5 JP2018529363 A5 JP 2018529363A5 JP 2018517183 A JP2018517183 A JP 2018517183A JP 2018517183 A JP2018517183 A JP 2018517183A JP 2018529363 A5 JP2018529363 A5 JP 2018529363A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- chimeric protein
- heterologous chimeric
- item
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 77
- 108020001507 fusion proteins Proteins 0.000 claims description 77
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 108010042215 OX40 Ligand Proteins 0.000 claims description 17
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 108010029697 CD40 Ligand Proteins 0.000 claims description 7
- 102100032937 CD40 ligand Human genes 0.000 claims description 7
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 7
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 7
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 5
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 3
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 3
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 3
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 3
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010017987 CD30 Ligand Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000743493 Homo sapiens V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021126595A JP7303254B2 (ja) | 2015-10-01 | 2021-08-02 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| JP2023102740A JP2023112132A (ja) | 2015-10-01 | 2023-06-22 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235727P | 2015-10-01 | 2015-10-01 | |
| US62/235,727 | 2015-10-01 | ||
| US201562263313P | 2015-12-04 | 2015-12-04 | |
| US62/263,313 | 2015-12-04 | ||
| US201662372574P | 2016-08-09 | 2016-08-09 | |
| US62/372,574 | 2016-08-09 | ||
| PCT/US2016/054598 WO2017059168A1 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126595A Division JP7303254B2 (ja) | 2015-10-01 | 2021-08-02 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529363A JP2018529363A (ja) | 2018-10-11 |
| JP2018529363A5 true JP2018529363A5 (enExample) | 2019-11-07 |
| JP6981973B2 JP6981973B2 (ja) | 2021-12-17 |
Family
ID=58424302
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517183A Active JP6981973B2 (ja) | 2015-10-01 | 2016-09-30 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| JP2021126595A Active JP7303254B2 (ja) | 2015-10-01 | 2021-08-02 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| JP2023102740A Pending JP2023112132A (ja) | 2015-10-01 | 2023-06-22 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126595A Active JP7303254B2 (ja) | 2015-10-01 | 2021-08-02 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| JP2023102740A Pending JP2023112132A (ja) | 2015-10-01 | 2023-06-22 | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (14) | US10183060B2 (enExample) |
| EP (2) | EP4183451B1 (enExample) |
| JP (3) | JP6981973B2 (enExample) |
| KR (1) | KR20180051651A (enExample) |
| CN (3) | CN116063566A (enExample) |
| AU (3) | AU2016331076B2 (enExample) |
| BR (1) | BR112018006578A2 (enExample) |
| IL (4) | IL316210A (enExample) |
| MX (2) | MX389750B (enExample) |
| PH (1) | PH12018500694A1 (enExample) |
| RU (2) | RU2766200C1 (enExample) |
| SA (1) | SA518391219B1 (enExample) |
| SG (5) | SG10201913591SA (enExample) |
| UA (1) | UA126549C2 (enExample) |
| WO (1) | WO2017059168A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US12533312B2 (en) | 2011-02-04 | 2026-01-27 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| WO2018127918A1 (en) * | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
| HRP20230937T1 (hr) | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
| WO2018127916A1 (en) * | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| CN118184797A (zh) | 2017-02-27 | 2024-06-14 | 沙塔克实验室有限公司 | 基于vsig8的嵌合蛋白 |
| IL268198B2 (en) * | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
| BR112019017713A2 (pt) * | 2017-02-27 | 2020-04-07 | Shattuck Labs Inc | proteínas quiméricas à base de csf1r |
| EP3600378A4 (en) * | 2017-03-24 | 2020-12-23 | Orpheus Bioscience Inc. | PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS |
| KR20180120893A (ko) * | 2017-04-28 | 2018-11-07 | 재단법인 목암생명과학연구소 | Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도 |
| EP3658165A4 (en) * | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | ONCOLYTIC VIRAL VECTORS AND THEIR USES |
| CN109646678A (zh) * | 2017-10-12 | 2019-04-19 | 中国科学院上海生命科学研究院 | Sun2蛋白、其制药用途及药物 |
| CN108384795A (zh) * | 2017-10-13 | 2018-08-10 | 江苏西迪尔生物技术有限公司 | 作用于tme免疫效应细胞的人工合成基因及验证方法和应用 |
| EP3700938A1 (en) * | 2017-10-26 | 2020-09-02 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | Novel recombinant fusion proteins, preparation and use thereof |
| CN111601823B (zh) * | 2017-11-07 | 2024-09-24 | 德克萨斯大学体系董事会 | 用car-t或car-nk细胞在癌症治疗中靶向lilrb4 |
| US12448415B2 (en) | 2018-01-04 | 2025-10-21 | Washington University | Compositions and methods for inhibition of alphavirus infection |
| KR102171766B1 (ko) * | 2018-02-02 | 2020-10-29 | 주식회사 뉴라클제네틱스 | Pd-l1 결합력이 증대된 pd-1 변이체 |
| EP3795585A4 (en) * | 2018-05-16 | 2022-03-16 | Genome and Company | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER WITH LRIT2 INHIBITOR AS AN ACTIVE SUBSTANCE |
| WO2019222547A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| AU2019290192A1 (en) * | 2018-06-21 | 2021-01-07 | Shattuck Labs, Inc. | Heterodimeric proteins and uses thereof |
| KR20210044220A (ko) * | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| SG11202013170RA (en) * | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| TW202023625A (zh) | 2018-08-23 | 2020-07-01 | 美商西雅圖遺傳學公司 | 抗tigit抗體 |
| WO2020047328A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising pd-1-based chimeric proteins |
| AU2019333173A1 (en) * | 2018-08-29 | 2021-03-11 | Shattuck Labs, Inc. | Combination therapies |
| WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
| AU2019328305A1 (en) * | 2018-08-29 | 2021-03-04 | Shattuck Labs, Inc. | Combination therapies comprising tim-3-based chimeric proteins |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| MX2021002289A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Proteinas quimericas basadas en flt3l. |
| CN109053902B (zh) * | 2018-09-11 | 2021-06-15 | 河南科技大学 | 一种嵌合蛋白aqp4-ch2、制备及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3893888A4 (en) * | 2018-12-10 | 2022-08-31 | Bioxcel Therapeutics, Inc. | COMBINATION THERAPIES FOR TREATING DISEASES USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST |
| CN113573782B (zh) * | 2018-12-21 | 2025-12-16 | Ose免疫疗法公司 | 针对人pd-1的双功能分子 |
| MX2021008022A (es) | 2019-01-07 | 2021-08-05 | Shattuck Labs Inc | Proteínas heterodiméricas para modular células t gamma delta. |
| US11098093B2 (en) * | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| AU2020208192A1 (en) * | 2019-01-14 | 2021-08-05 | Regents Of The University Of Minnesota | CD200AR ligands for cancer immunotherapy |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| CA3131259A1 (en) * | 2019-02-28 | 2020-09-03 | Shattuck Labs, Inc. | Combination therapies |
| AU2020276296A1 (en) * | 2019-05-16 | 2021-11-11 | Shattuck Labs, Inc. | NK cell-directed chimeric proteins |
| CN114585377A (zh) * | 2019-06-21 | 2022-06-03 | 沙塔克实验室有限公司 | 表达嵌合蛋白的t细胞 |
| CA3146248A1 (en) * | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| JP2022545439A (ja) * | 2019-08-21 | 2022-10-27 | アスクジーン・ファーマ・インコーポレイテッド | 新規ｉｌ－２１プロドラッグおよびその使用方法 |
| US20220306715A1 (en) * | 2019-08-30 | 2022-09-29 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
| CN112480237B (zh) * | 2019-09-12 | 2023-10-17 | 上海津曼特生物科技有限公司 | 一种融合蛋白及其制备方法和应用 |
| CN110592172B (zh) * | 2019-10-29 | 2021-05-28 | 华中农业大学 | 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点 |
| EP4058035A4 (en) * | 2019-11-14 | 2023-12-27 | Ludwig Institute for Cancer Research Ltd | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
| CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
| US20210230248A1 (en) * | 2020-01-25 | 2021-07-29 | Jun Chen | Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof |
| CN111849913B (zh) * | 2020-07-31 | 2021-05-25 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| AU2021370788A1 (en) * | 2020-10-26 | 2023-06-22 | Shattuck Labs, Inc. | Homodimeric and heterodimeric proteins comprising butyrophilin |
| WO2022094482A1 (en) * | 2020-11-02 | 2022-05-05 | Athae Bio, Inc. | Two-domain multimeric fusion proteins |
| JP2024500065A (ja) * | 2020-12-03 | 2024-01-04 | シャタック ラボ，インコーポレイテッド | Ｔｉｇｉｔベースのキメラタンパク質及びｌｉｇｈｔベースのキメラタンパク質を使用してがんを処置する方法 |
| KR102671409B1 (ko) * | 2021-03-02 | 2024-05-31 | 진화섭 | Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| IL305663A (en) * | 2021-03-05 | 2023-11-01 | Shattuck Labs Inc | Combined treatments with SIRPa-based chimeric proteins |
| WO2022187583A1 (en) * | 2021-03-05 | 2022-09-09 | Shattuck Labs, Inc. | Combination therapies with tim-3-based chimeric proteins |
| KR20220138909A (ko) * | 2021-04-06 | 2022-10-14 | 주식회사 이뮤노로지컬디자이닝랩 | Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| US20250092143A1 (en) * | 2021-07-23 | 2025-03-20 | University Of Southern California | Genetically engineered multifunctional exosomes for immunotherapy |
| WO2023019251A1 (en) * | 2021-08-12 | 2023-02-16 | Baylor College Of Medicine | Engineered soluble decoy receptors to enhance cancer immunotherapy |
| CA3236815A1 (en) * | 2021-11-01 | 2023-05-04 | Shattuck Labs, Inc. | Chimeric proteins for treating cutaneous inflammation |
| EP4453020A4 (en) * | 2021-12-23 | 2025-12-24 | Kahr Medical Ltd | LILRB POLYPEPTIDES AND THEIR USES |
| KR20240135646A (ko) * | 2022-01-20 | 2024-09-11 | 엑소큐어 스웨덴 에이비 | 막 단백질을 발현하는 재조합 세포주 및 이로부터 제조된 베지클 |
| JP2025522824A (ja) * | 2022-07-01 | 2025-07-17 | フェイト セラピューティクス，インコーポレイティド | 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| CN117886891B (zh) * | 2024-03-15 | 2024-06-07 | 黑龙江八一农垦大学 | 靶向巨噬细胞cd169受体的多肽及其应用 |
| CN120721960B (zh) * | 2025-08-19 | 2025-11-21 | 上海金域医学检验所有限公司 | 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ATE365209T1 (de) | 1992-05-14 | 2007-07-15 | Baylor College Medicine | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| AU6827094A (en) * | 1993-05-07 | 1994-12-12 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ES2219679T3 (es) | 1995-10-18 | 2004-12-01 | Akzo Nobel N.V. | Vacuna de combinacion contra la enfermedad de newcastle. |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| WO2001049318A1 (en) | 2000-01-03 | 2001-07-12 | Tr Associates, L.L.C. | Novel chimeric proteins and methods for using the same |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| CA2466279A1 (en) * | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| EP3020413A1 (en) * | 2002-01-30 | 2016-05-18 | The Brigham and Women's Hospital, Inc. | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
| JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| RU2369636C2 (ru) * | 2003-05-23 | 2009-10-10 | Уайт | Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения |
| MXPA06003686A (es) * | 2003-10-03 | 2007-03-01 | Brigham & Womens Hospital | Ligandos tim-3 y sus metodos. |
| JP2007531513A (ja) * | 2003-11-13 | 2007-11-08 | ハンミ ファーム．インダストリー カンパニー リミテッド | 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法 |
| MXPA06014126A (es) * | 2004-06-04 | 2007-07-18 | Regeneron Pharma | Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias. |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007133811A2 (en) | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| EP2038303A2 (en) * | 2006-06-21 | 2009-03-25 | Genentech, Inc. | Crystal structure of ox40l and ox40l complexed with ox40 receptor |
| WO2008061377A1 (en) * | 2006-11-22 | 2008-05-29 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| FI3056514T4 (fi) | 2008-01-15 | 2025-10-06 | Univ Leland Stanford Junior | Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi |
| EP2262531A1 (en) | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| HUE036780T2 (hu) * | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP5475766B2 (ja) | 2008-06-30 | 2014-04-16 | ユニバーシティ オブ ペンシルベニア | Ｆｎ１４／ＴＲＡＩＬ融合タンパク質 |
| WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
| BRPI0920749A8 (pt) * | 2008-10-02 | 2017-12-12 | Emergent Product Dev Seattle | Proteínas de ligação de antagonista multialvo cd86 |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| CN102257001A (zh) * | 2008-12-19 | 2011-11-23 | 诺瓦提斯公司 | 治疗自体免疫和炎性病症的可溶性多肽 |
| US9221895B2 (en) | 2009-03-13 | 2015-12-29 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
| JP2013514795A (ja) * | 2009-12-22 | 2013-05-02 | ノバルティス アーゲー | 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質 |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CA2812057A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| EP2697257B1 (en) * | 2011-04-13 | 2016-10-19 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| US8986688B2 (en) * | 2011-06-28 | 2015-03-24 | Inhibrx, Llc | WAP domain fusion polypeptides and methods of use thereof |
| CA2842368A1 (en) | 2011-07-29 | 2013-02-07 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
| CA2863818A1 (en) | 2012-02-06 | 2013-08-15 | Brendan CURTI | Cancer treatment and monitoring methods using ox40 agonists |
| MY174248A (en) * | 2012-04-30 | 2020-04-01 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| JP2015520192A (ja) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｈｉｐｐｏ経路を調節する結合剤およびその使用 |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9969789B2 (en) | 2012-12-17 | 2018-05-15 | Trillium Therapeutics Inc. | Treatment of CD47+ disease cells with SIRP alpha-Fc fusions |
| US10040841B2 (en) | 2013-01-01 | 2018-08-07 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
| US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
| WO2014121093A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP2961831B1 (en) | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| CN105121474B9 (zh) | 2013-03-12 | 2020-06-19 | 比奥孔有限公司 | 融合免疫调节蛋白及其制备方法 |
| JP6623353B2 (ja) * | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| KR20160065925A (ko) * | 2013-10-15 | 2016-06-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 응고 인자 vii 폴리펩티드 |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| MX2016007885A (es) * | 2013-12-17 | 2017-01-11 | Genentech Inc | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. |
| CA2934028A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| WO2015104406A2 (en) | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| EP3096782A4 (en) | 2014-01-21 | 2017-07-26 | Medlmmune, LLC | Compositions and methods for modulating and redirecting immune responses |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2015148416A1 (en) * | 2014-03-24 | 2015-10-01 | Deqiang Jing | Novel recombinant bi-functional fusion proteins, preparation and use thereof |
| US9718870B2 (en) | 2014-05-29 | 2017-08-01 | Medimmune, Llc | OX40L fusion proteins and uses thereof |
| EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| SG11201700629TA (en) | 2014-08-11 | 2017-02-27 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| AU2015303135B2 (en) | 2014-08-15 | 2021-05-20 | Merck Patent Gmbh | SIRP-alpha immunoglobulin fusion proteins |
| MX2017006320A (es) | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| EP3226900A4 (en) | 2014-12-05 | 2018-09-19 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| AU2015380455A1 (en) * | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| CN117964732A (zh) | 2015-08-07 | 2024-05-03 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
-
2016
- 2016-09-30 US US15/281,196 patent/US10183060B2/en active Active
- 2016-09-30 IL IL316210A patent/IL316210A/en unknown
- 2016-09-30 CN CN202211295685.8A patent/CN116063566A/zh active Pending
- 2016-09-30 CN CN201680001952.2A patent/CN108350055B/zh active Active
- 2016-09-30 SG SG10201913591SA patent/SG10201913591SA/en unknown
- 2016-09-30 EP EP22199596.2A patent/EP4183451B1/en active Active
- 2016-09-30 SG SG10201913573UA patent/SG10201913573UA/en unknown
- 2016-09-30 IL IL258029A patent/IL258029B/en unknown
- 2016-09-30 EP EP16852655.6A patent/EP3356393A4/en not_active Withdrawn
- 2016-09-30 RU RU2018111119A patent/RU2766200C1/ru active
- 2016-09-30 SG SG10201913597VA patent/SG10201913597VA/en unknown
- 2016-09-30 RU RU2022102624A patent/RU2022102624A/ru unknown
- 2016-09-30 JP JP2018517183A patent/JP6981973B2/ja active Active
- 2016-09-30 CN CN202211295776.1A patent/CN116063567A/zh active Pending
- 2016-09-30 IL IL303586A patent/IL303586B2/en unknown
- 2016-09-30 BR BR112018006578-1A patent/BR112018006578A2/pt not_active Application Discontinuation
- 2016-09-30 KR KR1020187012378A patent/KR20180051651A/ko active Pending
- 2016-09-30 MX MX2018004022A patent/MX389750B/es unknown
- 2016-09-30 IL IL295423A patent/IL295423B2/en unknown
- 2016-09-30 UA UAA201802923A patent/UA126549C2/uk unknown
- 2016-09-30 SG SG11201801984TA patent/SG11201801984TA/en unknown
- 2016-09-30 WO PCT/US2016/054598 patent/WO2017059168A1/en not_active Ceased
- 2016-09-30 SG SG10201913576RA patent/SG10201913576RA/en unknown
- 2016-09-30 AU AU2016331076A patent/AU2016331076B2/en active Active
-
2017
- 2017-11-06 US US15/804,533 patent/US10086042B2/en active Active
- 2017-12-22 US US15/853,241 patent/US10188701B2/en active Active
-
2018
- 2018-03-27 PH PH12018500694A patent/PH12018500694A1/en unknown
- 2018-03-28 MX MX2022001299A patent/MX2022001299A/es unknown
- 2018-03-28 SA SA518391219A patent/SA518391219B1/ar unknown
- 2018-06-29 US US16/024,228 patent/US10525102B2/en active Active
- 2018-06-29 US US16/024,226 patent/US10493128B2/en active Active
- 2018-06-29 US US16/024,214 patent/US10646545B2/en active Active
- 2018-06-29 US US16/024,218 patent/US10660936B2/en active Active
- 2018-06-29 US US16/024,209 patent/US10449233B2/en active Active
- 2018-11-28 US US16/203,469 patent/US10543253B2/en active Active
-
2019
- 2019-11-08 US US16/678,382 patent/US10653748B2/en active Active
-
2020
- 2020-03-09 US US16/813,165 patent/US12178847B2/en active Active
- 2020-04-08 US US16/843,029 patent/US11654180B2/en active Active
-
2021
- 2021-01-20 AU AU2021200367A patent/AU2021200367C1/en active Active
- 2021-08-02 JP JP2021126595A patent/JP7303254B2/ja active Active
- 2021-09-20 US US17/479,776 patent/US11547742B1/en active Active
-
2023
- 2023-06-22 JP JP2023102740A patent/JP2023112132A/ja active Pending
-
2024
- 2024-04-08 AU AU2024202253A patent/AU2024202253A1/en active Pending
- 2024-11-25 US US18/958,155 patent/US20250332219A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529363A5 (enExample) | ||
| RU2022102624A (ru) | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков | |
| JP7744479B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP7829773B2 (ja) | Ｉｌ２７受容体結合に関連する組成物および方法 | |
| JP6784687B2 (ja) | 結合誘発型転写スイッチ及びその使用方法 | |
| JP2020508068A5 (enExample) | ||
| JP2019519215A5 (enExample) | ||
| JP2020511949A5 (enExample) | ||
| CN113784986B (zh) | 间皮素特异性嵌合抗原受体及表达它的t细胞 | |
| WO2015037000A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| AU2015357463A1 (en) | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators | |
| CN112912400B (zh) | Nk接合子分子及其使用方法 | |
| JP2018519296A5 (enExample) | ||
| JP2020501550A5 (enExample) | ||
| WO2019006989A1 (zh) | 多功能融合蛋白及其应用 | |
| EA030147B1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
| RS64002B1 (sr) | Anti-kancerski fuzioni polipeptid | |
| JP2017507917A5 (enExample) | ||
| JP2022528020A (ja) | 癌の治療のための併用療法 | |
| JP2020536552A (ja) | Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用 | |
| JP2020536552A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| US20230303660A1 (en) | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation | |
| Awad et al. | Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade |